Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease

European Archives of Psychiatry and Clinical Neuroscience

Volumn 257, Issue 6, 2007, Pages 330-336

  Teipel, Stefan J ^a   Ewers, Michael ^a   Reisig, Veronika ^b   Schweikert, Bernd ^b   Hampel, Harald ^a   Happich, Michael ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Alzheimer's disease; ChE inhibitors; Cost effectiveness; Mortality; Quality of life

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH INSURANCE; HUMAN; MORTALITY; NURSING CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

AGED; ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DATA INTERPRETATION, STATISTICAL; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH STATUS INDICATORS; HUMANS; INDANS; LONG-TERM CARE; MALE; MARKOV CHAINS; NOOTROPIC AGENTS; PATIENT CARE PLANNING; PIPERIDINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 34748904805     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-007-0727-1     Document Type: Article

References (37)

1. (2003/II) Rote Liste®. Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, Aulendorf
2. Birks J, Iakovidou V, Tsolaki M (2000) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev: CD001191
3. Birks JS, Harvey R (2003) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev: CD001190
4. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N (2002) Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care 18: 497-507
5. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115
6. Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W (2005) Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci 229-230: 43-49
7. Gasper MC, Ott BR, Lapane KL (2005) Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother 3: 1-7
8. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51: 937-944
9. Gold MR, Siegel JE, Russell LB, M.C. W (1996) Cost-effectiveness in Health and Medicine. Oxford University Press, New York
10. Hallauer JF, Schons M, Smala A, Berger K (2000) Costs of medical treatment of Alzheimer patients in Germany. Gesundheitsökonomie & Qualitätsmanagement 5: 73-79
11. Hauber AB, Gnanasakthy A, Mauskopf JA (2000) Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 22: 439-451
12. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S (1998) Relation between severity of Alzheimer's disease and costs of caring. Cmaj 159: 457-465
13. Jönsson L, Lindgren P, Wimo A, Jonsson B, Winblad B (1999) The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 21: 1230-1240
14. Kemeny JG, Snell JL (1976) Finite Markov chains. Springer, New York
15. Kmietowicz Z (2005) NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ 330: 495
16. Loy C, Schneider L (2004) Galantamine for Alzheimer's disease. Cochrane Database Syst Rev: CD001747
17. Lu S, Hill J, Fillit H (2005) Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. Am J Geriatr Pharmacother 3: 92-102
18. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Jama 288: 1475-1483
19. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481-488
20. Neumann PJ (2005) Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis. Pharmacoeconomics 23: 537-541
21. Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, Kuntz KM, Bhattacharjya A (2001) Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology 57: 957-964
22. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC (1999) Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52: 1138-1145
23. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC (1999) Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 37: 27-32
24. Novella JL, Jochum C, Jolly D, Morrone I, Ankri J, Bureau F, Blanchard F (2001) Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res 10: 443-452
25. O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S (1999) Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J.Am Geriatr Soc 47: 570-578
26. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, Segura E (1993) The economic burden of Alzheimer's disease care. Health Aff (Millwood) 12: 164-176
27. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Group tDS (1998) A 24-week, double-blind, placebo-contolled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145
28. Ruof J, Mittendorf T, Pirk O, von der Schulenburg JM (2002) Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy 60: 59-66
29. Small GW, McDonnell DD, Brooks RL, Papadopoulos G (2002) The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc 50: 321-327
30. Statistik Bf (2004) Statistisches Jahrbuch. Metzler-Poeschel, Stuttgart
31. Steele C, Rovner B, Chase GA, Folstein M (1990) Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147: 1049-1051
32. Stewart A, Phillips R, Dempsey G (1998) Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 13: 445-453
33. Thompson S, Lanctot KL, Herrmann N (2004) The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 3: 425-440
34. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M (2003) Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 18: 306-313
35. Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W (2005) Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord 19: 178-183
36. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the panel on cost-effectiveness in health and medicine. Jama 276: 1253-1258
37. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495